Enlivex Therapeutics Secures Israeli Patent for Cancer Drug
Ticker: ENLV · Form: 6-K · Filed: Sep 9, 2025 · CIK: 1596812
Sentiment: bullish
Topics: patent, drug-development, israel
TL;DR
Enlivex just got an Israeli patent for Allocetra (cancer drug) until 2043. Big win for IP.
AI Summary
Enlivex Therapeutics Ltd. announced on September 9, 2025, the issuance of an Israeli patent for its drug candidate, Allocetra. This patent covers the use of Allocetra for treating certain types of cancer, specifically solid tumors, and is expected to provide market exclusivity in Israel until 2043.
Why It Matters
The new patent grants Enlivex market exclusivity in Israel for its Allocetra drug in treating solid tumors, potentially strengthening its commercial position and intellectual property portfolio.
Risk Assessment
Risk Level: medium — While a patent is positive, the impact is limited to Israel and the drug is still in development.
Key Numbers
- 2043 — Patent Exclusivity End Date (Market exclusivity in Israel for Allocetra)
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra (drug_candidate) — Subject of patent
- September 9, 2025 (date) — Announcement date
- 2043 (date) — Patent expiry
- Israel (country) — Jurisdiction of patent
FAQ
What specific types of cancer does the Israeli patent for Allocetra cover?
The Israeli patent covers the use of Allocetra for treating certain types of cancer, specifically solid tumors.
What is the expiration date of this new Israeli patent?
The patent is expected to provide market exclusivity in Israel until 2043.
What is the name of the drug candidate that received patent protection?
The drug candidate is named Allocetra.
On what date did Enlivex Therapeutics announce the issuance of this patent?
Enlivex Therapeutics announced the issuance of the patent on September 9, 2025.
In which country does this patent grant market exclusivity?
This patent grants market exclusivity in Israel.
Filing Stats: 234 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2025-09-09 08:05:12
Filing Documents
- ea0256508-6k_enlivex.htm (6-K) — 9KB
- ea025650801ex99-1_enlivex.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-085857.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: September 9, 2025 2